

# ANNUAL REPORT

2018



AUSTRALIA NEW ZEALAND  
GYNAECOLOGICAL ONCOLOGY GROUP



**ANZGOG's Head Office:**  
Australia New Zealand Gynaecological  
Oncology Group  
Level 6, Chris O'Brien Lifehouse  
119-143 Missenden Road  
CAMPERDOWN NSW 2050

**POSTAL:** Locked Bag M45, Missenden  
Road, NSW 2050

**Phone:** +61 2 8071 4880

**Fax:** + 61 2 8071 4888

**Email:** admin@anzgog.org.au

**ANZGOG's Melbourne office:**

Women's Cancer Foundation  
Suite 122, Level 1, 1 Queens Road  
MELBOURNE VIC 3004

**Phone:** +61 3 9867 3515

**Email:** contact@anzgog.org.au

We acknowledge the traditional owners of country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to elders both past and present and all Aboriginal and Torres Strait Islander people, from whatever nation they may come. In particular, we acknowledge the Gadigal people of the Eora nation, and the people of the Kulin nation as the traditional owners of the lands and waters where our offices are located.

For Māori, the indigenous people of Aotearoa New Zealand we acknowledge Papatuanuku as our Earth Mother, and it is from her bond with Ranginui, the sky father, that we, and all the plants and creatures on earth, descend. From this whakapapa or lineage, we are connected by a common bond and for us as Māori this translates into an obligation as kaitiaki or guardians to care for and protect our land and resources and to maintain their life sustaining properties for the benefit of present and future generations.

**The Australia New Zealand  
Gynaecological Oncology Group**  
is an Australian company limited by  
guarantee trading under the name  
Australia New Zealand Gynaecological  
Oncology Group or ANZGOG.

**ANZGOG** is registered for charitable  
fundraising in all States and Territories  
of Australia:

**Western Australia**  
Licence No. 21334

**Queensland**  
Reg No. CH2213

**New South Wales**  
Charitable Fundraising No. CFN/21451

**South Australia**  
Licence No. CCP1765

**Tasmania**  
File No. F1A-331

**Australian Capital Territory**  
Licence No. 19000383

**Victoria**  
Registration No. 11419.13

**Northern Territory**  
Reference No. 2010-4117

**ANZGOG** is a Health  
Promotion Charity.

**ANZGOG** is endorsed as a deductible.  
gift recipient under


Section 30-15 of the Income Tax  
Assessment Act 1997.

©2019

This report, or any part thereof, cannot be reproduced without the permission of the Australia New Zealand Gynaecological Oncology Group.  
All rights reserved.



# Contents



About  
ANZGOG  
01



Chair's  
Report  
03



Clinical  
Trials  
05



Publications  
13



TR-ANZGOG  
15



Collaborations  
17




Annual Scientific  
Meeting 2018  
18




Survivors Teaching  
Students  
22



Community  
Support  
28



Measuring Our  
Performance  
28



Board of  
Directors  
31



Financial  
Statements  
35

# About ANZGOG

The Australia New Zealand Gynaecological Oncology Group (ANZGOG) is the peak national gynaecological cancer research organisation. We are recognised as a world leader in clinical trials research.

Our mission is to improve life for women with ovarian and other gynaecological cancers through research, cooperative clinical trials, information and awareness.

ANZGOG's research has changed clinical practice both locally and globally. For more information please go to [www.anzgog.org.au](http://www.anzgog.org.au)


OUR  
MEMBERS

(as at 30 June 2018)

857



## Grouped by professional field




### Occupational Area

Gynaecological Oncology  
Medical Oncology  
Radiation Oncology  
Clinical Trial Coordination + Data Managers  
Nursing  
Behavioural Science + Lab researcher  
Fellow  
Trainee + Registrar + PhD Student  
Exercise + Psychology + Pharmacy  
Pathology  
Health Economics + Statistics  
Other  
Cancer Organisation + consumers  
Pharmaceutical/Industry



## Grouped by term of membership (4 categories)



Membership  
length



## Grouped by geo-location (11 locations)



### STATE

ACT  
NSW  
VIC  
QLD  
SA  
WA  
TAS  
NT  
North, NZ  
South, NZ  
Overseas



# Gynaecological Cancer

Gynaecological cancers originate in the female reproductive system. The main types of gynaecological cancers are ovarian, uterine, cervical and vulvar. Rarer types are vaginal cancer, fallopian tube cancer and placental cancer (which is pregnancy-related).



Every day in Australia **17** women are diagnosed with a gynaecological cancer



**5.6** women will die from a gynaecological cancer today

**54%**

of women with ovarian cancer will not survive 5 years after diagnosis

Women who carry a mutation in their BRCA1 or BRCA2 genes have an approximately 20% greater risk of developing ovarian cancer than women with normal BRCA genes.

**20%**



While survival across all cancers has improved by 19% over the past 25 years, the relative survival for all gynaecological cancers improved by just 7%.

**55%**

Endometrial cancer incidence has risen 55% in the last 10 years, partly due to the rise in obesity.



**1 in 20 women**

risk being diagnosed with a gynaecological cancer by the age of 85

Aboriginal and Torres Strait Islander women are 1.7x more likely to be diagnosed with gynaecological cancers – particularly uterine and cervical – than non-Indigenous women.

“Virtually every advance in cancer has been made on the back of clinical trials”

Associate Professor  
Alison Brand



The highest incidence of all gynaecological cancers is found in remote and very remote areas, second only to major cities.

# Chair's Report



A/PROF PHILIP BEALE |  
ANZGOG BSc, MBBS,  
FRACP, PhD

Dear Colleagues

The Annual Report gives me a chance to celebrate the many successes ANZGOG has had over the past year and thank the many people who have given generously of their time, energy and intellect to our organisation.

"I would like to recognise the contribution by Assoc Professor Alison Brand as Chair of ANZGOG over the past six years. During this time ANZGOG achieved financial stability and we strengthened both our culture of professional mentoring and leadership, increasing membership to almost 900 members. The annual trial portfolio increased significantly to more than 15 trials in development or recruiting patients." Said Assoc Professor Philip Beale.

**Clinical Trials** – ANZGOG is committed to building a research portfolio and where required self-fund research. Our goals include a spectrum of trials – Phase III trials, Phase II trials, signal-seeking trials and early-phase trials where we are looking for new avenues of care, and also supportive care. It is important that we draw on all of the domains of gynaecological cancer care: surgery, radiation, nursing, allied health and medical oncology.

This is being achieved through a variety of initiatives:

**OASIS** (Ovarian cancer Alliance for Signal-seeking Studies) – this initiative to test new targeted therapies against molecular sub-types of ovarian cancer is a series of innovative signal-seeking Phase II studies. ANZGOG has been successful growing funding for this initiative from an initial philanthropic seed funding grant of \$1.1million to now almost \$11million. Six studies are either recruiting or in development.

**Fund for New Research Grants** – with the vision of fostering new research ideas which will eventuate in a clinical trial, this grants scheme is funded by public donations and awards up

to \$50,000 each to a maximum of three pilot or pre-clinical research projects each year. Since inception ANZGOG has funded six studies with a further three identified for funding in 2018.

**Clinical Trials** – Along with the six OASIS studies, ANZGOG has a further nine studies either recruiting or in development through its collaborations with the University of Sydney, NHMRC Clinical Trials Centre. These studies include 'homegrown' studies by ANZGOG investigators and international collaborations through the Gynecologic Cancer InterGroup with such countries as Canada, the United Kingdom and Italy. These studies also represent the multi-disciplinary nature of ANZGOG with surgical and exercise physiology clinical trials as well as immunotherapy and medical oncology treatments.

**Funding for research** – ANZGOG achieved funding in 2017-2018 year for the Stics and Stones study from NHMRC and funding and drug support for Solace 2 from Astra Zeneca.

In the last 5 years from 2013-2018 ANZGOG has had 1597 patients recruited across 16 studies. We are continuing to build our research portfolio to ensure more trials are available for patients, which hopefully means better care and better opportunities for treatment, but also further knowledge within the treatment of gynaecological cancers.

**Translational ANZGOG** – a significant initiative is TR-ANZGOG which addresses the critical need to collect biospecimens associated with clinical trials for research into biomarkers, molecular signatures, identification of therapeutic targets and other translational studies. After wide consultation we were able to secure funding and a Project Manager to start this initiative in 2018.






ANZGOG membership has more than doubled to 857 members in the last five years with members from all Australian States and Territories and all

*"ANZGOG has achieved significant growth. In 2018 our annual portfolio of trials more than doubled in number to 15, and more trials are expected to commence in the coming year; we have achieved financial stability; and are strengthening our capabilities in translational research."*

parts of New Zealand. These members include clinicians, scientists, consumers, trial coordinators, nurses, data managers, exercise physiologists, health economists and biostatisticians.

We engage with them through our Annual Scientific Meeting in April, tumour working groups and our annual Research Development Day in November. We have a very active volunteer group within our membership with more than 100 members taking part in committees, workings groups, education sessions and other activities to mentor members and support our research.

**Strategic Goals** – ANZGOG reviewed its 2013-2018 Strategic Plan and defined its goals for the next five years through to 2023 in May 2019. These goals are:

-  **GOAL 1:** Innovative and equitable clinical trials in gynaecological cancers.
-  **GOAL 2:** World-class translational research in gynaecological cancers.
-  **GOAL 3:** Capacity building for gynaecological cancer research in Australia and New Zealand.
-  **GOAL 4:** Strategic partnerships, collaboration and engagement.
-  **GOAL 5:** Organisational capacity aligned with our research agenda.

We will continue to develop further maturity in our organisational capability and financial sustainability to support our gynaecological cancer research goals in an efficient and streamlined manner. This is supported through a range of activities not least of which is ANZGOG's commitment to public fundraising and philanthropy.

**Thank you to our Supporters** - We have an outstanding array of supporters helping us fundraise for research and the conduct of clinical trials at hospitals. These include individual


fundraisers, women sharing their stories in the media, on Facebook and our websites, companies and organisations that run events and fundraisers, thank you all.

I would like specifically to acknowledge the ongoing passion provided by Duncan McPherson, AM, and his tireless work with the Team Teal harness racing industry initiative #getrealsupportteal. Together with Michael Taranto over \$495,000 has been raised for ANZGOG over the last 2 years.

Charlie Brown is another significant supporter of ANZGOG and has taken on the role of Ambassador at Large for ANZGOG and the 'Save the Box' fundraising initiative promoting awareness of gynaecological cancers and the need for further funding for research.

**Survivors Teaching Students®** is another outstanding initiative. This volunteer program brings the faces and voices of ovarian cancer survivors and caregivers into the classrooms of health professional students to teach them about women's experience with ovarian cancer diagnosis and treatment. Over 800 students were reached in year one of the program with 18 presentations to medical schools completed. The program is now rolling out across Australia. We thank the outstanding contribution by so many women and their families supporting this program.

Our people are our strength and I want to thank all ANZGOG members, staff and our supporters who have contributed to another successful year for clinical research in Australia and New Zealand.



**A/PROF PHILIP BEALE | CHAIR ANZGOG**  
BSc, MBBS, FRACP, PhD



## GOAL 01

### Clinical Research

Undertake a diverse portfolio of clinically important research in gynaecological cancer that has the greatest potential to improve patient outcomes.

*"We need to continue to develop better treatments as well as access to preventive measures, so more women in Australia and around the world can live a long and happy life."*

Associate Professor Linda Mileskin - ANZGOG Director



# Clinical Trials



## RECRUITING

<b>Study</b>	<b>ECHO</b>
<b>Title</b>	A Phase III randomised, controlled trial of exercise during chemotherapy for patients commencing first line treatment for ovarian cancer.
<b>Principal Investigator</b>	Sandi Hayes
<b>Collaborations</b>	Initiated in Australia by ANZGOG
<b>Contact:</b>	echo@ctc.usyd.edu.au
<b>Funding:</b>	Cancer Australia; World Cancer Research Fund
<b>Sites:</b>	Recruiting across 8 sites
<b>Study</b>	<b>AUTO-CHECK</b>
<b>Title</b>	Molecular determinants of autoimmunity and immune-related adverse events in advanced cancer patients treated with immune checkpoint inhibitors.
<b>Principal Investigator</b>	A: Matthew Cook B: Sonia Yip
<b>Collaborations</b>	Initiated in Australia under the Genomic Cancer Clinical Trials Initiative (GCCTI) involving multiple cancer co-operative trials groups: ANZGOG, ALTG, ANZUP and COGNO.
<b>Contact:</b>	autocheck@ctc.usyd.edu.au
<b>Funding:</b>	Cancer Australia
<b>Sites:</b>	Recruiting across 6 studies
<b>Study</b>	<b>EMBRACE</b>
<b>Title</b>	A Phase II clinical trial of the PARP inhibitor, olaparib, in HR-deficient metastatic breast and relapsed ovarian cancer in patients without germline mutations in BRCA1 and BRCA2.
<b>Principal Investigator</b>	Katrin Sjoquist
<b>Collaborations</b>	Initiated in Australia in collaboration with ANZGOG and Breast Cancer Trials
<b>Contact:</b>	embrace@ctc.usyd.edu.au
<b>Funding:</b>	Cancer Australia
<b>Sites:</b>	Recruiting across 4 sites

# Clinical Trials

## RECRUITING CONT.

Study	STATEC
<b>Title</b>	A randomised trial of non-selective versus selective adjuvant therapy in high risk apparent stage 1 endometrial cancer.
<b>Principal Investigator</b>	Alison Brand
<b>Collaborations</b>	Gynecologic Cancer InterGroup (GCIG) trial led by Cancer Research UK, ANZGOG lead group for Australia and New Zealand.
<b>Contact:</b>	statec@ctc.usyd.edu.au
<b>Funding:</b>	NHMRC Project Grant
<b>Sites:</b>	Recruiting across 8 sites

Study	feMMe
<b>Title</b>	A Phase II randomised clinical trial of Mirena® ± Metformin ± weight loss intervention in patients with early stage cancer of the endometrium
<b>Principal Investigator</b>	Andreas Obermair
<b>Collaborations</b>	Initiated in Australia by the Queensland Centre for Gynaecological Cancer collaboratively with ANZGOG.
<b>Contact:</b>	ao@surgicalperformance.com
<b>Funding:</b>	Lord Mayors Community Trust; UQ Academic Title Holders Grant; Cherish Women's Cancer Foundation; RBWH Foundation; Cancer Australia; ANZGOG.
<b>Sites:</b>	Recruiting across 17 sites



## IN DEVELOPMENT

Study	ICON9
<b>Title</b>	An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy.
<b>Principal Investigator</b>	Linda Mileschkin
<b>Collaborations</b>	Gynecologic Cancer InterGroup (GCIG) trial led by Cancer Research UK, ANZGOG lead group for Australia and New Zealand.
<b>Contact:</b>	icon9@ctc.usyd.edu.au



## IN DEVELOPMENT CONT.

<b>Funding:</b>	Cancer Australia
<b>Sites:</b>	17 sites planned
<b>Study</b>	<b>SOLACE2</b>
<b>Title</b>	A Phase II randomised trial comparing immune priming by low dose oral cyclophosphamide plus olaparib versus priming by olaparib alone, prior to combination therapy with olaparib plus durvalumab, versus single agent olaparib alone, in asymptomatic platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancers with homologous recombination repair defects.
<b>Principal Investigator</b>	Clare Scott & Chee Lee Magdalena Plebanski (Translational Chair)
<b>Collaborations</b>	Initiated in Australia by ANZGOG
<b>Contact:</b>	solace2@ctc.usyd.edu.au
<b>Funding:</b>	AstraZeneca; ANZGOG OASIS Initiative Grant
<b>Sites:</b>	15 sites selected
<b>Study</b>	<b>AtTEND</b>
<b>Title</b>	Phase III Double-blind Randomised Placebo Controlled Trial of Atezolizumab in Combination with Paclitaxel and Carboplatin in Women with Advanced/Recurrent Endometrial Cancer.
<b>Principal Investigator</b>	Yoland Antill
<b>Collaborations</b>	Led by the Mario Negri Gynecologic Oncology group (MaNGO), Italy; ANZGOG lead group for Australia and New Zealand.
<b>Contact:</b>	attend@ctc.usyd.edu.au
<b>Funding:</b>	MaNGO supported by Roche
<b>Sites:</b>	18 sites planned
<b>Study</b>	<b>STICs and STONeS</b>
<b>Title</b>	A randomized phase II double-blind placebo-controlled trial of acetylsalicylic acid (ASA) in chemoprevention of ovarian cancer in women with BRCA 1 and 2 mutations.
<b>Principal Investigator</b>	Kelly-Anne Phillips
<b>Collaborations</b>	Canadian Cancer Trials Group (CCTG), Canada; ANZGOG lead group for Australia and New Zealand.

# Clinical Trials

## IN DEVELOPMENT CONT.

<b>Contact:</b>	stics@ctc.usyd.edu.au
<b>Funding:</b>	NHMRC Project Grant
<b>Sites:</b>	6 sites planned
<b>Study</b>	<b>MOCCA</b>
<b>Title</b>	A multicentre Phase II randomised trial of durvalumab (MEDI4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinomas.
<b>Principal Investigator</b>	Michael Friedlander
<b>Collaborations</b>	National University Health System (NUHS) Singapore led international trial, ANZGOG lead group for Australia and New Zealand.
<b>Contact:</b>	research@anzgog.org.au
<b>Funding:</b>	NUHS supported by AstraZeneca
<b>Sites:</b>	5 sites planned



## CLOSED TO RECRUITMENT

<b>Study</b>	<b>REZOLVE</b>
<b>Title</b>	A Phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant ovarian cancer.
<b>Principal Investigator</b>	Katrin Sjoquist
<b>Collaborations</b>	Initiated in Australia by ANZGOG
<b>Contact:</b>	rezolve@ctc.usyd.edu.au
<b>Funding:</b>	Cancer Australia; seed funding from the University of Sydney and Ovarian Cancer Research Foundation.
<b>Study</b>	<b>PHAEDRA</b>
<b>Title</b>	A Phase II trial of durvalumab (MEDI4736) in advanced endometrial cancer.
<b>Principal Investigator</b>	Yoland Antill
<b>Collaborations</b>	Initiated in Australia by ANZGOG
<b>Contact:</b>	phaedra@ctc.usyd.edu.au
<b>Funding:</b>	AstraZeneca
<b>Sites:</b>	Recruiting across 12 sites





Study	VIP
<b>Title</b>	Phase II study of intravenous Vinorelbine in patients with relapsed platinum resistant or refractory C5 high grade serous, endometrioid, or undifferentiated primary peritoneum, fallopian tube or ovarian Cancer.
<b>Principal Investigator</b>	Linda Mileschkin
<b>Collaborations</b>	National University Health System (NUHS) Singapore led international trial, ANZGOG lead group for Australia and New Zealand.
<b>Contact:</b>	research@anzgog.org.au
<b>Funding:</b>	ANZGOG OASIS Initiative Grant
<b>Sites:</b>	Recruiting across 2 of 5 proposed sites.
Study	iPRIME
<b>Title</b>	A Phase II study of durvalumab (MEDI4736) and tremelimumab in combination with neoadjuvant carboplatin and paclitaxel in newly diagnosed women with advanced high grade serous ovarian, fallopian tube and peritoneal cancers.
<b>Principal Investigator</b>	Tarek Meniawy
<b>Collaborations</b>	Initiated in Australia by ANZGOG
<b>Contact:</b>	trials@anzgog.org.au
<b>Funding:</b>	AstraZeneca (TRiPRIME funded by ANZGOG OASIS Initiative Grant)
<b>Sites:</b>	10 sites selected
Study	PRECISE
<b>Title</b>	A Phase II signal-seeking trial of the clinical benefit rate associated with pamiparib in subjects with germline or somatic BRCA1/2 high grade serous ovarian cancer or carcinosarcoma who have progressed on P-gp substrate chemotherapy or PARP inhibitors with the presence of an ABCB1 fusion and the absence of a BRCA1/2 reversion.
<b>Principal Investigator</b>	Ali Freimund
<b>Collaborations</b>	Initiated in Australia by ANZGOG
<b>Contact:</b>	trials@anzgog.org.au
<b>Funding:</b>	BeiGene, ANZGOG OASIS Initiative Grant

# Centres Participating In ANZGOG Trials

As at 30 June 2018

## KEY

- Site currently open to recruitment
- Site selected but not yet open

	ECHO	feMMe	PHAEDRA	STATEC	ICON9	VIP	iPRIME	EMBRACE
QUEENSLAND		●						
	●	●						
			●		●			●
	●	●	●		●		●	
		●						
			●					
	●							
								●
	●	●			●			●
		●			●	●		
	●	●						
			●		●			
NEW SOUTH WALES	●				●			
	●				●			
								●
					●			
					●			
					●			
					●			
					●			
					●			
					●			
			●		●	●	●	
						●	●	
	●	●	●					

		ECHO	feMMe	PHAEDRA	STATEC	ICON9	VIP	iPRIME	EMBRACE
NEW SOUTH WALES	Royal North Shore Hospital								●
	St George Hospital							●	●
	Westmead Hospital	●			●	●	●	●	●
ACT	Canberra Hospital	●				●			
VICTORIA	Border Medical Oncology						●		●
	Monash Medical Centre - Clayton		●					●	
	Monash Medical Centre - Moorabbin			●					
	Mercy Hospital for Women			●					
	Peter MacCallum Cancer Centre			●		●	●	●	●
	The Royal Women's Hospital	●	●		●				
	Cabrini Hospital			●					
TASMANIA	Royal Hobart Hospital				●	●			
SOUTH AUSTRALIA	Flinders Medical Centre				●	●			
	Royal Adelaide Hospital								●
	King Edward Memorial Hospital		●						
WESTERN AUSTRALIA	Sir Charles Gairdner Hospital			●		●			
	St John of God Hospital, Subiaco		●		●			●	
	St John of God Hospital, Murdoch				●				
	Fiona Stanley Hospital								●
	Hollywood Private Hospital				●				
	Linear Clinical Research							●	
	Auckland Hospital		●						
NEW ZEALAND	Christchurch Hospital		●		●	●			
	Wellington Hospital		●						

# Publications

## 2018 Abstracts

1. Sjoquist, K.M., L.R. Mileskin, S.Ananda, C.M. Shannon, D. Bowtell, S. Yip, D. Espinoza, J.C. Goh, M.L. Harrison, M. Plebanski, V. Gebiski, M.R. Stockler, K. Livingstone, M. Tang, and M. Friedlander, REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal (IP) bevacizumab (bev) for recurrent ascites in advanced, chemotherapy-resistant, epithelial ovarian cancer (CR-EOC). *Journal of Clinical Oncology*, 2018. 36(15\_suppl): p. 10097-10097DOI: 10.1200/JCO.2018.36.15\_suppl.10097.

## 2018 Manuscripts

2. de Boer, S.M., M.E. Powell, L. Mileskin, D. Katsaros, P. Bessette, C. Haie-Meder, P.B. Ottevanger, J.A. Ledermann, P. Khaw, A. Colombo, A. Fyles, M.H. Baron, I.M. Jurgenliemk-Schulz, H.C. Kitchener, H.W. Nijman, G. Wilson, S. Brooks, S. Carinelli, D. Provencher, C. Hanzen, L. Lutgens, V. Smit, N. Singh, V. Do, R. D'Amico, R.A. Nout, A. Feeney, K.W. Verhoeven-Adema, H. Putter, C.L. Creutzberg, and P.s. group, Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. *Lancet Oncol*, 2018. 19(3): p. 295-309DOI: 10.1016/S1470-2045(18)30079-2.
3. Friedlander, M., J. Rau, C.K. Lee, W. Meier, A. Lesoin, J.W. Kim, A. Poveda, M. Buck, G. Scambia, M. Shimada, F. Hilpert, M.T. King, P. Debruyne, A. Bologna, S. Malander, B.J. Monk, E. Petru, P. Calvert, T.J. Herzog, C. Barrett, and A. du Bois, Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy. *Ann Oncol*, 2018. 29(3) p. 737-743DOI: 10.1093/annonc/mdx796.
4. Wilson, M.K., R. Mercieca-Bebber, and M. Friedlander, A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer. *J Gynecol Oncol*, 2018. 29(5): p. e81DOI: 10.3802/jgo.2018.29.e81.
5. King, M.T., M.R. Stockler, R.L. O'Connell, L. Buizen, F. Joly, A. Lanceley, F. Hilpert, A. Okamoto, E. Aotani, J. Bryce, P. Donnellan, A. Oza, E. Avall-Lundqvist, J.S. Berek, J. Sehouli, A. Feeney, D. Berton-Rigaud, D.S.J. Costa,

M.L. Friedlander, and G.S.B. group, Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. *Qual Life Res*, 2018. 27(1): p. 59-74DOI: 10.1007/s11136-017-1729-8.

6. Beesley, V.L., D.D. Smith, C.M. Nagle, M. Friedlander, P. Grant, A. DeFazio, P.M. Webb, and O.S. Group, Coping strategies, trajectories, and their associations with patient-reported outcomes among women with ovarian cancer. *Support Care Cancer*, 2018DOI: 10.1007/s00520-018-4284-0.

## 2017 Abstracts

7. Clamp, A.R., I. McNeish, A. Dean, D. Gallardo, J. Weon-Kim, D. O'Donnell, J. Hook, C. Coyle, S.P. Blagden, J. Brenton, R. Naik, T. Perren, S. Sundar, A. Cook, E. James, A.M. Swart, S. Stenning, R. Kaplan, and J. Ledermann, 929O\_PRICON8: A GCIg phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression-free survival (PFS) analysis. *Annals of Oncology*, 2017. 28(suppl\_5): p. mdx440.039-mdx440.039DOI: 10.1093/annonc/mdx440.039.

## 2017 Manuscript

8. Park, S.B., J.B. Kwok, R. Asher, C.K. Lee, P. Beale, F. Selle, and M. Friedlander, Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial. *Ann Oncol*, 2017. 28(11): p. 2733-2740DOI: 10.1093/annonc/mdx491.
9. Rungruang, B.J., A. Miller, T.C. Krivak, N.S. Horowitz, N. Rodriguez, C.A. Hamilton, F.J. Backes, L.F. Carson, M. Friedlander, D.G. Mutch, M.J. Goodheart, K.S. Tewari, R.M. Wenham, M.A. Bookman, G.L. Maxwell, and S.D. Richard, What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study. *Cancer*, 2017. 123(6): p. 985-993DOI: 10.1002/cncr.30414.



# Fund For New Research Grants

The Fund for New Research Grants support pilot and pre-clinical studies that are identified as providing data that may lead to a clinical trial and also supports innovative sub-studies and young or new investigator's studies. Each year a maximum of three grants up to \$50,000 are offered. Two studies were funded in the 2017-2018 year.

<b>Study</b>	<b>PHAEDRA Translational Sub-study</b>
<b>Title</b>	Molecular and Genomic correlations with clinical response to Durvalumab in Advanced Endometrial Cancer
<b>Principal Investigator</b>	Amanda Spurdle
<b>Collaborations</b>	ANZGOG collaboration with QIMR Berghofer Medical Research Institute
<b>Contact:</b>	Amanda.spurdle@qimrberghofer.edu.au
<b>Sites:</b>	N/A

<b>Study</b>	<b>EMBRACE Translational Sub-study</b>
<b>Title</b>	Understanding resistance and sensitivity to PARP inhibitors in Homologous Recombination deficient (HRD) high grade serous ovarian cancer; translational research from the EMBRACE clinical trial.
<b>Principal Investigator</b>	Katrin Sjoquist
<b>Collaborations</b>	ANZGOG collaboration with NHMRC Clinical Trials Centre, University of Sydney
<b>Contact:</b>	Katrin.Sjoquist@ctc.usyd.edu.au
<b>Sites:</b>	N/A

Also supported by ANZGOG in 2017-2018:

<b>Study</b>	<b>WHAM (What happens after menopause?) A multi centre prospective study.</b>
<b>Title</b>	Impact of risk reducing bilateral salpingo-oophorectomy on non-cancer outcomes in young high risk women.
<b>Principal Investigator</b>	Martha Hickey
<b>Collaborations</b>	ANZGOG collaboration with The Royal Women's Hospital, Melbourne
<b>Contact:</b>	hickeym@unimelb.edu.au
<b>Funding:</b>	ANZGOG grant

## GOAL 02

### Translational Research

Build capacity for translational research in gynaecological cancer through the development of a national gynaecological cancer biobank.

*"TR-ANZGOG will add a whole new dimension to gynae-cancer clinical trials in Australasia. It has the potential to benefit not only Australian women, but women around the world diagnosed with gynaecological cancers. Clinical trials tell us whether a particular drug or intervention improves survival. TR-ANZGOG helps us to investigate WHY the drug tested in the trial works, or doesn't work, at an individual patient level."*

Professor Anna de Fazio, Chair,  
TR-ANZGOG Steering Committee

# TR-ANZGOG

TR-ANZGOG is an ANZGOG research initiative established to achieve a strategic goal to build capacity for translational research by supporting the collection of biospecimens associated with all ANZGOG trials. Additionally it aims to provide enduring custodianship and maximize the use of biospecimens through research.

2018 marked the next phase of TR-ANZGOG implementation following funding success and commencement of a Project Manager, Claire Davies. Claire is a medical scientist, specialising in Anatomical Pathology. With over fifteen years' career experience in diagnostic and clinical research environments (primarily gynaecological oncology), both locally and internationally, Claire brings to TR-ANZGOG broad expertise and knowledge in translational research processes.

A TR-ANZGOG steering committee has been established, Chaired by Prof Anna de Fazio. The committee is comprised of a diverse panel of experts whose specialties include pathology, clinical trial management, pure science research, surgery, oncology, ethics and operations. Members include A/Prof Philip Beale, A/Prof Lyndal Anderson, Prof Clare Scott, A/Prof Pamela Pollock, Prof David Bowtell, A/Prof Alison Brand, Dr Alison Davis, Dr Michelle Vaughan and A/Prof Linda Mileshekin.

Preliminary work has focussed on strategy planning, connecting with key people and securing further funding for TR-ANZGOG.

ANZGOG would like to thank the Rose Varga Bequest and the John T Reid Charitable Trusts for their support, in recognition of the importance of the TR-ANZGOG initiative.

TR-ANZGOG is an exciting opportunity in our aim to improve outcomes for women with gynaecological cancer by stimulating new translational research projects and clinical trials, and by promoting collaboration.





## GOAL 03

### Collaboration

Build capacity for gynaecological cancer research in Australia through collaboration with relevant national and international groups with a focus on Asia.

*ANZGOG's international collaborations are fostered through its membership of the Gynecologic Cancer InterGroup with 28 member countries. Our focus on Asia has brought two trials to Australia and more are in development.*

*Collaborations with institutions such as Sydney and Melbourne Universities, Walter Eliza Hall Medical Research Institute, QIMR Berghofer, Queensland University of Technology and University of Western Australia are ensuring a diverse approach to research ideas and clinical trial development.*



# 2018 Annual Scientific Meeting

## CHALLENGES IN PRECISION GYNAECOLOGICAL CANCER IN A MOLECULAR ERA

The 2018 ANZGOG Annual Scientific Meeting (ASM) took place in Brisbane from 4 to 7 April, with the theme "Challenges in Precision Gynaecological Cancer in a Molecular Era". A total of 235 members of ANZGOG attended the ASM.

The ANZGOG ASM gives researchers, clinicians, nurses and clinical research officers the opportunity to hear about the research being generated by ANZGOG and its international collaborators. It is also an opportunity to build collaborations with overseas guests and their research units, and learn about new approaches to gynaecological cancer treatment.

The 2018 ASM theme focused on the many challenges in this new era of targeted therapy, including:

- Improving efficacy of novel targeted therapies by using combinations of drugs
- Availability, timing and access to tumour testing
- Cost and access to targeted therapies
- Identifying those patients likely to respond to novel agents
- How to appropriately measure the impact of treatments on quality of life

## INTERNATIONAL GUEST SPEAKERS

Three world-leading clinical researchers spoke at the ASM.

**Dr Martee Hensley from Memorial Sloan Kettering Cancer Center in New York, USA** gave the first plenary presentation on the

challenges of caring for women with uterine sarcomas – a rare group of diseases, many with a very poor prognosis, even when diagnosed at an early stage. Dr Hensley spoke of the opportunity to explore how molecular testing may improve diagnostic classification and precision, whether molecular profiling may yield prognostic information, and whether such testing can identify potential treatment targets for a subset of patients. Her talk highlighted the challenges of treating women with these rare gynaecological malignancies.

**Professor Michael Milosevic, Radiation Oncologist from Princess Margaret Cancer Centre, Toronto, Canada** spoke about cervical cancer, which remains a global health problem. Few, if any, drugs have been identified previously that, when combined with curative radiotherapy, both improve treatment response and reduce side effects. Professor Milosevic spoke about an exciting novel drug that in pre-clinical models of cervical cancer does precisely that, and it is hoped that this agent will soon enter clinical trials.

**Associate Professor Jessica McAlpine, a Gynaecological Oncologist from the British Columbia Cancer Agency in Vancouver, Canada** spoke about endometrial cancer - the most common gynecologic cancer in the developed world, increasing in both incidence and mortality. Associate Professor McAlpine's talk reviewed the need for, evolution of, and applications (tested and intended) for novel molecular classifiers in endometrial cancer.

Highlight presentations from local presenters included sessions on Immunotherapy, Quality of Life and Survivorship, Translational ANZGOG and Pathology, and a presentation about ANZGOG's Survivors Teaching Students awareness program.

# 2018 Annual Scientific Meeting

## AWARDS PRESENTATIONS

**General Oral Abstract:** a tie between Associate Professor Penny Webb, and Professor Michael Friedlander who presented “The hidden burden of anxiety and depression in ovarian cancer: a prospective longitudinal study from diagnosis”; and “Getting the most out of follow-up: a prospective study using the Measure of Ovarian Symptoms and Treatment concerns (MOST) symptom index to evaluate and track adverse effects (AEs) and detect symptoms of recurrence in patients with ovarian cancer (OC) following first line chemotherapy (1LT)”

**Poster award:** Dr Rachel Delahunty, “TRACEBACK: Finding BRCA1 and BRCA2 mutations in women with ovarian cancer diagnosed prior to changes to genetic testing guidelines”

**Pure Science Oral Abstract Award:** Dr Gwo-Yaw Ho, “Eribulin as a novel treatment candidate for ovarian and fallopian tube derived carcinosarcoma”

**Pure Science Poster Award:** a tie between Dr Emily Colvin, “Expression of lncRNAs in ovarian cancer-associated fibroblasts is prognostic for patient survival”; and Luqman Jubair whose work was presented by PhD supervisor Professor Nigel McMillan, “Gene editing using CRISPR/CAS9 highly effective for HPV-driven cancers”

## PUBLIC FORUM: CHALLENGING THE STATUS-QUO OF WOMEN'S CANCERS

A Public Forum was held immediately following the ASM on the Saturday afternoon to provide insights into ANZGOG's research and cancer treatments for women with a gynaecological cancer, their families and friends. The Forum attracted 45 attendees from Brisbane, Melbourne, Adelaide and Perth, with an additional 333 viewing online from major cities and regional towns across Australia.

Presentations on recent developments and new trials in the three main tumour types were delivered by Associate Professor Alison Brand (endometrial), Dr Paul Cohen (cervical), and Professor Clare Scott (ovarian). Two presentations were given from ovarian cancer survivors and volunteers with the Survivors Teaching Students (STS) program, Jane Power and Kristen Larsen. Dr Helen Gooden presented on STS and Julijana Trifunovic promoted opportunities to raise funds for ANZGOG's research through our major fundraising campaigns.

# Thank you to our Sponsors



Michael Milosevic and Paul Cohen



Clockwise from top left: Philip Beale, Paul Cohen, Michael Milosevic, Jessica McAlpine, Martee Hensley.



Michael Friedlander AM, and Alison Davis



Go for Gynae Walk ASM



Platinum Sponsor & Pure Science Session Sponsor



Gold Sponsor



Workshop Sponsor



Session Sponsor



Exhibitors



Exhibitors



Exhibitors



Best of the Best Awards



Best of the Best Awards



## GOAL 04

### Leadership

Be recognised as the leader in gynaecological cancer research in Australia and New Zealand, by clinicians, consumers and cancer organisations.

*Engaging with women, their families and friends to raise awareness about gynaecological cancer research has fostered an amazing army of supporters for ANZGOG's work. Along with leadership through our Annual Scientific Meeting, ANZGOG now conducts education for trainees, forums for the public and education for doctors and nurses through Survivors Teaching Students.*





Survivors Teaching Students® (STS) is a volunteer program that brings the faces and voices of ovarian cancer survivors and caregivers into the classrooms of health professional students to teach them about women's experiences with the disease. ANZGOG is leading the program here in Australia.

We have now completed our first full year of STS having started in 2017 after being awarded a Cancer Australia Supporting people with cancer Grant, funded by the Australian Government, to establish the program over the three year period 2017 – 2020, with a requirement that the program continues beyond this initial period.

Due to the high demand from schools and interest from women and caregivers affected by ovarian cancer, we are out-performing our specified goals in the first year of operation.


### Key Achievements (FY 2017-18):

#### Enrolled 6 university programs in two states - NSW and Victoria



Recruited and trained/training 60 volunteers from across Australia.

Delivered 9 presentations, reaching 300 students medical and nursing students



Pre and post-evaluations showed effectiveness percentages for medical schools of 23% and 32% for nursing (under and postgraduate) compare favourably with the US Program



Presented Survivors Teaching Students at 4 national conferences

Due to the nature of the disease, we are always recruiting new volunteers and welcome enquiries to take part in the program. Our pool of volunteers is always changing due to the demands of the disease, advancing illness and at times, death.

ANZGOG is committed to our duty of care to our STS volunteers. We value the support of two psycho-oncologists, Cath Adams and Toni Lindsay, who work with us in STS to ensure our survivors work safely in the STS program.



# Community Support

## Save the Box Launch

On Thursday 30 August 2018, ANZGOG launched the inaugural 'Save the Box' brunch at the Nobel Trust Suite at the Sydney Cricket Ground, with Women in Sport, to recognise International Gynaecological Cancer Awareness Month.

The Save the Box Launch "More Precious than Gold" brunch brought together women in sport and women living with a gynaecological cancer, or those affected by it. We began the conversation with a beautiful brunch and a robust panel discussion on the eve of International Gynaecological Cancer Awareness Month. The panel talked about the importance of women and sport, and the importance of raising awareness and talking openly with your peers, family and work colleagues about women's health issues.

**Gretel Killeen**, who was fabulous as the guest host, introduced our special guest panel:

**The Hon. Stuart Ayres MP** – NSW Minister for Sport

**Heather Hawkins** – Ovarian Cancer survivor and Ultramarathon champion

**Associate Professor Philip Beale** – Chair of ANZGOG

**Alicia Quirk OAM** – Australian Rugby Union Player, Olympics Gold Medalist

**Katrina Cochrane** – Network Leader, Australian Fitness Network

**Sarah Hill** - CEO Greater Sydney Commission, National Rower, Director NSW Rowing

Special thank you to Gretel and all of the panel members for kindly donating their time for our event.



Save the Box Launch

# Community Support

## Save the Box Community Activities in Focus

**Sally Catt** inspiringly swam against huge tides to cross the English Channel and raised \$7,550 for Save the Box. The swim took 14 hours and 8 minutes- setting off in the dark at 11pm from the English coast. Sally swam in recognition and support of her friend Caitlin Delaney who was diagnosed with stage 4 ovarian cancer in January 2017.

**Alisha Thompson** - has raised just under \$22,500 for Save the Box and has since increased her target to a lifetime goal of \$100,000! Alisha has stage 4 ovarian cancer and is focused on raising funds for gynaecological cancer research and in equal importance, raising awareness of gynaecological cancer symptoms and the importance of research into these cancers.



Sally Catt



Alisha Thompson

**Fiona Price** and her seven friends decided on a dramatic approach to fundraising and settled on jumping out of a plane at 11,000 feet! The eight women put on their Save the Box t-shirts and leapt out over the blue skies of Tasmania, raising \$9,000!



Fiona Price, second from right, top row



# Community Support

## WOMEN'S CANCER FOUNDATION

### We Can Walk it Out 2018

We Can Walk it Out 2018, now in its 16th year, was a great event for the Women's Cancer Foundation. With over 500 adults, children and dogs in attendance, the weather was perfect. Key Ambassadors attended the event showing their commitment and support for women with a gynaecological cancer. Denise Scott was once again fabulous as the MC, with Jana Pittman helping with the warm up and speaking about cervical cancer and Charlie Brown (Ambassador at Large) acknowledging and thanking all of the participants on behalf of ANZGOG.



Karen Livingstone AM, Jana Pittman, Denise Scott, Charlie Brown



Team Francis Flyers

### Team Teal 2018

This year Team Teal, where the Harness Racing fraternity supports Women's Cancer Foundation, went one step further by going international! Harness Racing New Zealand has now also taken up the reins to support ovarian cancer research. Throughout Australia and New Zealand, reinswomen wear teal pants on the track and race against each other and men, to try and cross the finish line first, where \$200 is donated by the club and then matched by the wagering group. Other fundraising activities also take place around the track, such as teal cupcakes, merchandise selling and raffles.

The activity that runs over a six week period, through February to mid-March, is now a significant event in the Harness Racing Industry thanks to Duncan McPherson OAM and Michael Taranto, Chairman of Harness Racing Australia. They have agreed on a three year partnership and hope to increase our fundraising targets significantly in the future. This year the event raised over \$155,000.



Team Teal



# Community Support

## Night at the Trots

What a fabulous night! In total, over \$92,000 was raised. Held annually at TABCORP Park in Melton Victoria and hosted by Harness Racing Victoria, this year's event attracted 350 people in attendance. The Lyn McPherson Memorial Race is the signature race, where everyone remembers those we have lost to ovarian cancer.

Special thanks to Patron and founder Duncan McPherson OAM and Michael Taranto, Chairman of Harness Racing Australia, for their support. Also thank you to the sponsors, prize donors and everyone who attended.



Night at the Trots



Tom McPherson (left) and Duncan McPherson OAM (right)

## Marathon for Women's Cancer Foundation



Thomas (Tom) and Duncan McPherson OAM, long-time supporters of Women's Cancer Foundation, have upped the ante with their fundraising for research into ovarian and gynaecological cancer. Their fundraising began when Tom's mother (Duncan's wife) Lyn, passed away in 2010 from ovarian cancer. This year together (a first for Duncan) they took part in the Iron Man competition, taking on the half marathon in Busselton (WA) and raised over \$21,500! We would like to thank the McPherson family for their continued commitment to the Women's Cancer Foundation and ANZGOG.

## GO For Gynae and other ANZGOG Fundraising Activities

### GO Step for Gynae

The month of May acknowledges fitness, ovarian cancer and cancer research so we felt what better month to do GO Step for Gynae in 2018. There has been a large increase in women being diagnosed with endometrial cancer and one contributing factor is the obesity epidemic. Over \$22,000 was raised, with Jill Emberson raising the most at \$8,000. Thank you to everyone who participated.

### Women in Drinks – The Drinks Association

In 2018 Women in Drinks throughout Australia once again came together and raised over \$15,000 at their International Women's Day event at Luna Park in Sydney, and also fundraised throughout the year at their state networking events. We are extremely grateful for their ongoing support of ANZGOG's work.



## GOAL 05

### Financial Sustainability

Become a financially sustainable organisation, not reliant on grant funding for core business by 2018.

*"ANZGOG is in a very strong financial position. Our balance sheet is very good with total equity of \$5,229,685 and programs are in place to continue growth and funding for research."*

Mr David Rogers, Non-Executive Finance Director,  
ANZGOG Board



# Measuring Our Performance

Actions and Measurables	2016	2017	2018
<b>SG1 –A diverse portfolio of clinically important research in gynaecological cancers</b>			
<b>Grow diversity of research portfolio to include earlier phase clinical trials</b>			
■ Number of ovarian cancer trials underway	3	2	8
■ Number of endometrial cancer trials underway	2	3	3
■ Number of cervical cancer trials underway	1	1	2
■ Number of Quality of Life studies underway	3	1	0
■ Other types of trials including rare tumour studies underway	1	1	0
<b>Foster new research ideas and support via collaborations and funding</b>			
■ Fund for New Research Grants awarded	3	2	2
■ OASIS Initiative Grants awarded	1	3	0
■ Collaborative studies supported by ANZGOG	2	8	12
<b>In partnership with government and collaborators we continue to increase the opportunities for women to participate in gynaecological cancer clinical trials</b>			
■ Increase the number of gynaecological cancer clinical trials conducted annually	9	8	13
■ Increase the number of clinical sites actively participating in gynaecological cancer clinical trials (including international sites conducting ANZGOG collaborative studies) **	529	433	49
■ Increase participation in clinical trials by women affected with gynaecological cancer ** [2017 - two major trials closed to recruitment, OUTBACK and Symptom Benefit]	761	1004	105
<b>Translating research into practice</b>			
■ Number of publications of research results	11	23	7
■ Trials changing clinical practice	ICON7	–	Portec 3
<b>Develop independent cancer clinical trials to the stage of applying for grant and other funding [in collaboration with the NHMRC Clinical Trials Centre]</b>			
■ Government grants awarded for research and research support	\$1,335,701	\$964,954	\$1,299,086
■ Other funding provided for research and research support	\$489,121	\$583,035	\$622,801
<b>Clinical trials design and protocol development</b>			
■ Number of new concepts or studies presented to ANZGOG	25	26	22
■ Number of new concepts in development with ANZGOG	6	6	14
<b>Increase the professional capacity to conduct clinical trials in Australia through member growth, education and training in clinical trials design</b>			
■ Number of people attending Annual Scientific Meetings	262	231	235
■ Increase in clinical professionals joining as members	703	770	857

# Measuring Our Performance

Actions and Measurables	2016	2017	2018
<b>SG2 - Set up a national gynaecological cancer biobank</b>			
<b>Build capacity for translational research in gynaecological cancer through the development of a national gynaecological cancer biobank</b>			
■ Establish a working group to explore the options and identify steps to achieve	Draft strategy in consultation	TR-ANZGOG Strategy Approved	TR-ANZGOG Project Manager appointed
<b>SG3 – Build gynaecological cancer research capacity</b>			
<b>Build collaboration with national organisations</b>			
■ Number of collaborations with other cancer clinical trials groups	3	5	4
<b>Build collaboration with international groups working in the gynaecological cancer research</b>			
■ Increase in international sites conducting ANZGOG trials **	428	336	0
■ Number of collaborations with international gynaecological cancer groups **			
DGOG - Holland , AGO - Germany, GINECO - France, EORTC - Belgium , ICORG – Ireland, RTOG – USA, NCIC – Canada, NSGO – Denmark, MITO – Italy, NSGO – Sweden, JGOG – Japan, GOG - USA, COGI – USA, HOG – USA, SGCTG - Scotland, UCL – United Kingdom, CRUK - United Kingdom, MRC – United Kingdom, GOTIC - Japan	15	5	6
■ International keynote speakers at Annual Scientific Meetings	4	3	3
<b>SG4 – recognised as the leader in gynaecological cancer research</b>			
<b>Communicate the breadth of ANZGOG's research focus</b>			
■ Twice annual ResearchHER for consumers and the general public	Achieved	Achieved	Achieved
■ Twice annual TRIALS – in-depth news on gynaecological cancer trials for members and cancer professionals	Achieved	Achieved	Once
<b>We support new research ideas with funding to get started.</b>			
■ New Research Grants awarded	3	3	2
<b>Raising awareness of clinical trials amongst consumers</b>			
■ Number of participants in consumer information sessions in person and through webinars	65	389	378
■ Number of likes on Facebook (established 21 July 2014)	4,593	7,532	14,504
<b>Raising awareness of clinical trials amongst the public</b>			
■ Number of general public reached via information events	2000+	2,319	1,527

# Measuring Our Performance

Actions and Measurables	2016	2017	2018
<b>Growing capacity of consumers supporters</b>			
■ Conduct two education and training programs for our consumer advisory panel annually	Achieved	Achieved	Achieved
■ Number of Volunteer Ambassadors supporting ANZGOG	9	17	147
<b>SG5</b>			
<b>Growing support from non-government sectors for gynaecological cancer research</b>			
■ Increase donations, bequests, community support	\$812,269	\$806,179	\$2,430,048
■ Gain on acquisition of Womens' Cancer Foundation			-
■ Increase corporate sponsorship	\$123,866	\$208,927	\$193,191
■ Number of bequests per annum	1	1	1
<b>Supporting Infrastructure costs with grants</b>			
■ Percentage of infrastructure costs supported by grants	81.2%	89.3%	71.1%
<b>Growing and maintaining our investments to cover 12 months of operational expenditure, to secure us against future funding shortfalls.</b>			
■ Months of operational expenditure covered by cash reserves	20.2	26.6	27.3
■ Investment return per annum	1.4%	1.3%	1.6%
<b>Our people</b>			
<b>In collaboration with the NHMRC Clinical Trials Centre (CTC) we have an engaged and skilled paid workforce.</b>			
■ ANZGOG staff, headcount excluding casuals [and as FTE]	8 [5.6 FTE]	9 (6.4FTE)	13 (8.6 FTE)
■ CTC staff working on ANZGOG trials, headcount	8	8	8



# Board of Directors



## ASSOCIATE PROFESSOR PHILIP BEALE

Associate Professor Beale is Director of Cancer Services and Director of Palliative Care, Sydney Local Health District, Head of Medical Oncology Department at Concord Hospital, Senior Staff Specialist at RPA, and at Chris O'Brien Lifehouse and Associate Professor at the University of Sydney. He has a special interest in ovarian, breast, colorectal and upper gastrointestinal cancers and is involved in Phase I, II and III clinical trials for all of these cancers and is the PI in several breast and ovarian cancer trials. He has published more than 100 peer reviewed papers. He is the Chair of ANZGOG and is a member of the AGITG and ANZBCTG trials groups.



## ASSOCIATE PROFESSOR ALISON BRAND

Alison Brand is a gynaecological oncology surgeon, Director of Gynaecological Oncology at Westmead Hospital, Sydney, NSW and Clinical Associate Professor at the University of Sydney and has been involved in ANZGOG since it was established in 2000 and has since held key positions within the group. She was Chair of the group from 2012 to 2018. She is the Australian PI for the STATEC endometrial cancer surgical trial. She has chaired or been a member of several working parties for the development of national gynaecological cancer guidelines. She was Senior Editor for the International Journal of Gynaecological Cancer. She is passionate about participation in clinical trials as a way to improve the lives of women with gynaecological cancers, now and in the future.



## MS SUE BREW

Sue Brew has been a member of the ANZGOG Study Coordinators' committee since its inception in 2005 and accepted the position as committee chair in 2011. She has been a Study Coordinator in the Department of Medical Oncology, Calvary Mater Newcastle since 1996 and also recently served as member of Hunter New England Human Research Ethics Committee for a period of 8 years 2006 – 2014.



## DR ALISON DAVIS

Alison Davis is a Senior Staff Specialist in Medical Oncology at The Canberra Hospital and Conjoint Senior lecturer at the Australian National University. Her subspecialty areas include gynaecological and breast cancer and she is actively involved in clinical research in both areas. Her other interest areas include Cancer Genetics and end of life care. Alison has been involved with ANZGOG for many years and was Deputy Chair of the ANZGOG RAC for two years before becoming Chair in late 2017. She has also been a member of the ANZGOG Audit, ASM and New Research Fund Committees, as well as a member of other regional and national organisations including Advisory Committee Pharmaceutical Medicines 2008-2015, ACT SE NSW Breast Cancer Treatment Group, and Australian Breast Cancer Tissue Bank.



## DR JEFFREY GOH

Jeff Goh is a Senior Staff Medical Oncologist (part-time) at Royal Brisbane & Women's Hospital (RBWH) and a Visiting Medical Oncologist at Greenslopes Private Hospital and ICON Chermiside. He is also involved with the University of Queensland as a Senior Lecturer with the Faculty of Medicine. Jeff has been actively involved in clinical trials including his role as Principal Investigator in a number of Phase I, II and III Gynaecological and Urological malignancy trials at Royal Brisbane & Women's Hospital and Greenslopes Private Hospital. He is currently a co-investigator for several colorectal cancer and pulmonary malignancy trials. Jeff is also currently a board member of ANZGOG and chairs the Cervical Tumour Type Working Group. His particular interests are in gynaecological, urological and colorectal malignancies.



## DR PEARLY KHAW

Dr Pearly Khaw is a Radiation Oncologist at the Peter MacCallum Cancer Centre. She is also a clinical researcher and is leading the Radiation Oncology Quality Assurance Program of the PORTEC-3 trial in Australia through the Trans-Tasman Radiation Oncology Group (TROG). Dr Khaw has been a reviewer for the International Journal of Gynecological Cancer, Journal of Medical Imaging and Radiation Oncology, and Practical Radiation Oncology. She was involved in the formation of the Special Interest Group for Radiation Oncologists practising in the area of Gynae-Oncology through the Royal Australian and New Zealand College of Radiologists. Pearly is a Primary Investigator on the ANZGOG endometrial trial STATEC.



# Board of Directors



## ASSOCIATE PROFESSOR LINDA MILESHKIN

Linda Mileshkin is a clinical researcher who has achieved productive research output whilst maintaining a significant and busy clinical role as a consultant medical oncologist, with a particular interest in the treatment of gynaecological and lung cancers, as well as the supportive care of people affected by cancer. She runs the only specialist Carcinoma of Unknown Primary clinic at the Peter MacCallum Cancer Centre. She is currently involved in multiple clinical research projects involving people with gynaecological and lung cancers, carcinoma of unknown primary (CUP), as well as Phase I trials in multiple tumour types. Linda is currently the international study chair for Outback, an international Australia-led NHMRC funded Phase III trial in cervical cancer.



## PROFESSOR CLARE SCOTT

Clare Scott is a Medical Oncologist at the Royal Melbourne Hospital and Royal Women's Hospital and Laboratory Head at the Walter and Eliza Hall Institute of Medical Research, studying drug resistance in ovarian cancer. She has 15 years' experience in clinical cancer genetics, including working in Familial Cancer Clinics and in treating breast and ovarian cancer. In the lab, she focuses on ovarian biology, including the role of apoptosis in infertility and on developing targeted therapies for ovarian cancer in novel ovarian cancer models. She has been awarded a Clinical Fellowship from the Victorian Cancer Agency (2011) and the Sir Edward Dunlop Cancer Research Fellow from the Cancer Council Victoria (2012). Clare is co-chair of the SOLACE2 trial.



## ASSOCIATE PROFESSOR PETER SYKES

Peter Sykes is a gynaecological oncologist and Head of Department in Obstetrics and Gynaecology, Christchurch School of Medicine, University of Otago, Christchurch, New Zealand. He completed his initial training in Bristol, UK and has worked in both Australia and New Zealand. His interest area of clinical research in the epidemiology and management of gynaecological cancer has involved a steady record of publication in clinical gynaecological oncology. He has actively recruited and treated patients in international multicentre and single centre research. He is on the ANZGOG Research Advisory Committee and was Program Chair of the 2014 ANZGOG ASGO Combined Scientific Meeting and was Program Chair of the 2015 ANZGOG Annual Scientific Meeting.



## MR DAVID ROGERS

David Rogers was with accounting, tax and consulting professional services firm KPMG for 37 years; including 27 years as a partner in the Australian firm. His career has included audit partner and lead partner for many significant companies in a wide range of sectors. In addition, David was a member of the firm's National Board of directors for six years from 2005 to 2011, including two years as Chairman of the firm's Audit Committee, and was prior to his retirement leader of the firm's global audit transformation project.

David is currently a Director and Deputy Chair of the Royal Motor Yacht Club Broken Bay, a member of the Western Sydney Local Health District's Finance, Performance and Assets Committee and an independent consultant to clients involved in disputes concerning accounting and financial audit matters.



## MS RACHAEL SUTTON

Rachael is a Partner in the Holman Webb Workplace Relations group and has 19 years' experience in employment and workplace law. Rachael is experienced in all aspects of workplace laws and has a strong background in advising public and private sector employers. Rachael was admitted to practice law in October 1997 and has been a partner at Holman Webb since January 2012. She also specialises in food safety and labelling laws and has acted as a prosecutor for the NSW Food Authority for some 14 years. She now advises food businesses, including start-ups in this area. Rachael has presented to many Boards of Directors and senior management teams on employment and work health and safety laws, what due diligence means and how best to comply. Rachael is a member of the NSW Law Society and Industrial Relations Society of NSW.

# Our Committees

## RESEARCH ADVISORY COMMITTEE

Alison Davis (Chair)  
Michelle Vaughan  
(Deputy Chair)  
Lyndal Anderson  
Cheryl Waller  
Rhonda Beach  
Candace Carter  
Martin Stockler  
Monica Tang  
Val GebSKI  
Sonia Yip  
Alison Brand  
Sam Saidi  
Philip Beale  
Michael Friedlander AM  
Clare Scott  
Peter Sykes  
Michelle Wilson  
Wanda Lawson  
Jermaine Coward  
Sandi Hayes  
Pamela Pollock  
Ganessan Kichenadasse  
David Bowtell  
Peter Grant  
Anne Hamilton  
Linda MilesHkin  
Pearly Khaw  
Tarek Meniawy  
Joanne Youd

## UTERINE TUMOUR GROUP

Diana Adams (Chair until  
February)  
Yoland Antill (Chair from  
April 2018))  
Rhonda Farrell (Co. Chair  
from April 2018)  
Elizabeth Barnes  
Cheryl Waller  
Peey Sei Kok  
Srinivas Kondalsamy-  
Chennakesavan  
Andrea Garrett  
Amanda Spurdle  
Eva Baxter  
Pamela Pollock  
Ganessan Kichenadasse  
Mahesh Iddawela  
Pearly Khaw  
Rachel Delahunt

## OVARIAN TUMOUR GROUP

Philip Beale (Chair)  
Tarek Meniawy (Deputy Chair  
from April 2018)  
Rhonda Beach  
Anthony Richards  
Janine Lombard  
Michael Friedlander AM  
Monica Tang  
Rachel O'Connell  
Anna de Fazio  
Bryony Simcock  
Kathryn Chrystal  
Michelle Wilson  
Alison Hadley  
Catherine Shannon  
Jermaine Coward  
David Bowtell  
Clare Scott  
Sumitra Ananda

## CERVIX TUMOUR GROUP

Jeffrey Goh (Chair)  
Michelle Harrison  
(Deputy Chair from April 2018)  
Sam Saidi  
Felicia Roncolato  
Karen Lim  
Kristy Robledo  
Sonia Yip  
Wanda Lawson  
Vivek Arora  
Anne Hamilton  
Kailash Narayan  
Ming Yin Lin

## QUALITY ASSURANCE COMMITTEE

Pearly Khaw (Chair)  
Alison Brand  
Michelle Harrison  
Belinda Egan  
Alison Hadley  
Philip Chan  
Mahesh Iddawela  
Ganendra Raj Kader Ali Mohan

## STUDY COORDINATORS COMMITTEE

Sue Brew (Chair)  
David Cannan  
Donna Long  
Kathryn Jenkins  
Belinda Egan  
Elizabeth Wardrop  
Jenny Campbell  
Meghan Leigh  
Vanessa Taylor  
Melissa Groom  
Joanne Youd

## CONSUMER AND COMMUNITY COMMITTEE

Helene O'Neill (Chair to April  
2018 – 10 years service)  
Pennie Stoyles (CCC member to  
April 2018 – 10 years service)  
Wanda Lawson (Chair of  
Consumer Research Panel from  
April 2018)  
Cheryl Waller  
Rhonda Beach  
Lisa Finucane  
Lesley McQuire  
Fiona Price  
Kathryn Cornthwaite

## OASIS STEERING COMMITTEE

Michael Friedlander AM (Chair)  
Sue Brew  
Philip Beale  
Alison Brand  
Bo Gao  
Chee Khoon Lee  
Anna de Fazio  
Michelle Wilson  
Karen Livingstone  
David Bowtell  
Clare Scott  
Linda MilesHkin  
George Au-Yeung  
Tarek Meniawy

## AUDIT RISK COMMITTEE

David Rogers  
Philip Beale  
Rachael Sutton

## NOMINATIONS COMMITTEE

Philip Beale  
Alison Brand  
Michael Friedlander AM  
Carol Johnson  
Danny Rishin

## ANZGOG CTC OPERATIONS EXECUTIVE COMMITTEE

Philip Beale  
Alison Brand  
Alison Davis  
Martin Stockler  
Candace Carter  
John Andrews  
Peey Sei Kok  
Elisa Carolus  
Alison Evans

## ANZGOG RESEARCH MANAGEMENT GROUP

Philip Beale  
Alison Brand  
Alison Davis  
Michelle Vaughan  
Alison Evans  
Tracey Meares

# Our Structure





# Financial Statements

(abbreviated)

## FUNDING RESEARCH

### Government grant support

ANZGOG and the University of Sydney NHMRC Clinical Trials Centre (CTC) have a collaborative agreement together which supports the development and operation of many ANZGOG clinical trials.

Government grant funding for the benefit of ANZGOG clinical trials projects is administered by the University of Sydney and is received annually to support research activities.

In 2018 \$1,921,887 in government grants and other funding was achieved via the University of Sydney for ANZGOG's research, bringing the total since 2002 to \$19,543,217.

These funds are not reported in the ANZGOG Annual Financial Statements but are received in addition to our other fundraising achievements.

### Research project funding

Significant trial funds received and administered by the University of Sydney in 2018 were:

Solace2	\$425,000
STICs & STONeS	\$311,831
PHAEDRA	\$185,400
STATEC	\$232,649

### Support for clinical trials

The Cancer Australia Support for Cancer Clinical Trials Program, which is shared 50:50 with the NHMRC Clinical Trials Centre, provides \$230,000 annually and this figure is included in income statements.

ANZGOG was awarded the Cancer Australia Support for Clinical Trials Program grant in 2018 for a further 3 years from 2018 to 2021.

### Philanthropic and other grants

Funds were received in 2018 for a number of new research and education initiatives. They are held in non-current liabilities until expensed. At 30 June 2018 these were:

OASIS Initiative Research Projects	\$425,000
Survivors Teaching Students®	\$311,831

In addition in 2018, the Rose Varga Bequest was given to benefit ovarian cancer research conducted under the OASIS Initiative and is held in ANZGOG Reserves for future use on OASIS projects.

# Financial Statements


(abbreviated)

## ANZGOG INCOME 2018

Revenue	2018 \$	2017 \$
Government grant	546,731	372,765
Trial projects	458,660	274,484
Philanthropic grant	107,808	34,430
Fundraising activities	2,533,997	806,179
Corporate sponsorship	193,191	208,927
Annual Scientific Meeting conference	124,691	137,734
Interest income	26,533	13,663
Dividend income	54,218	11,358
Rental income	18,034	33,008
Gain on sale of property	35,000	—
<b>Total income</b>	<b>4,098,863</b>	<b>1,892,548</b>

## Annual Income with Surplus

Income Total Income including Surplus



The Annual Financial Report for the Year Ending 30 June 2018, audited by BDO can be viewed here: <https://www.acnc.gov.au/charity/anzgog>


# Financial Statements

(abbreviated)

## BALANCE SHEET

	2018 \$	2017 \$
<b>Current assets</b>		
Cash and cash equivalents	2,684,895	3,783,386
Trade and other receivables	573,552	462,693
<b>Total current assets</b>	<b>3,258,447</b>	<b>4,246,079</b>
<b>Non-current assets</b>		
Plant and equipment	13,606	8,379
Intangible assets	10,816	-
Available-for-sale financial assets	3,158,760	177,780
Investment properties	230,000	570,000
Total non-current assets	3 413,182	756,159
<b>Total assets</b>	<b>6,671,629</b>	<b>5,002,238</b>
<b>Current liabilities</b>		
Trade and other payables	1,377,340	1,527,976
Employee benefits	64,604	50,108
<b>Total current liabilities</b>	<b>1,441,944</b>	<b>1,578,084</b>
<b>Total liabilities</b>	<b>1,441,944</b>	<b>1,578,084</b>
<b>Net assets</b>	<b>5,229,685</b>	<b>3,424,154</b>
<b>Equity</b>		
Available for sale financial assets reserve	9,701	3,665
New Research Fund reserve	499,350	547,983
Beneficiary Fund reserve	224,053	227,989
OASIS Initiative reserve	2,085,933	-
<b>Retained surplus</b>	<b>2,410,648</b>	<b>2,644,517</b>
<b>Total equity</b>	<b>5,229,685</b>	<b>3,424,154</b>

## Equity



The Annual Financial Report for the Year Ending 30 June 2018, audited by BDO can be viewed here: <https://www.acnc.gov.au/charity/anzgog>

# Financial Statements

(abbreviated)

## CASH FLOWS

	2018 \$	2017 \$
<b>Cash flows from operating activities</b>		
Receipts from grants	792,919	1,472,196
Receipts from donations	2,430,048	671,213
Receipts from sponsorships, Annual Scientific Meeting conference, insurance recoveries and other revenue	442,593	349,170
Payments to suppliers and employees	(2,209,666)	(1,453,077)
<b>Net cash inflow from operating activities</b>	<b>1,455,894</b>	<b>1,039,502</b>
<b>Cash flows from investing activities</b>		
Payments for purchase of plant & equipment	(11,578)	(2,263)
Payments for purchase of intangible assets	(10,816)	-
Purchase of investments	(2,974,945)	-
Dividend income from investments	54,219	11,358
Interest received	26,533	13,663
Cash received on sale of investment property	362,202	-
<b>Net cash (outflow)/inflow from investing activities</b>	<b>(2,554,385)</b>	<b>22,758</b>
<b>Net (decrease)/increase in cash and cash equivalents</b>	<b>(1,098,491)</b>	<b>1,062,260</b>
Cash and cash equivalents at the beginning of the year	3,783,386	1,631,126
Cash acquired on amalgamation	-	1,090,000
<b>Cash and cash equivalents at the end of the year</b>	<b>2,684,895</b>	<b>3,783,386</b>





Tel: +61 2 9251 4100  
Fax: +61 2 9240 9821  
www.bdo.com.au

Level 11, 1 Margaret St  
Sydney NSW 2000  
Australia

## INDEPENDENT AUDITOR'S REPORT

To the members of Australia New Zealand Gynaecological Oncology Group

### Report on the Audit of the Financial Report

#### Qualified opinion

We have audited the financial report of Australia New Zealand Gynaecological Oncology Group (ANZGOG), which comprises the statement of financial position as at 30 June 2018, the statement of profit or loss and other comprehensive income, the statement of changes in equity and the statement of cash flows for the year then ended, and notes to the financial report, including a summary of significant accounting policies, and the directors' declaration.

In our opinion, except for the effects of the matter described in the *Basis for qualified opinion* section of our report, the accompanying financial report of ANZGOG, is in accordance with Division 60 of the Australian Charities and Not-for-profits Commission Act 2012, including:

- (i) Giving a true and fair view of the company's financial position as at 30 June 2018 and of its financial performance for the year then ended; and
- (ii) Complying with Australian Accounting Standards - Reduced Disclosure Requirements and Division 60 of the Australian Charities and Not-for-profits Commission Regulation 2013.

#### Basis for qualified opinion

Cash donations are a significant source of fundraising revenue for ANZGOG. ANZGOG has determined that it is impracticable to establish control over the collection of cash donations prior to entry into its financial records. Accordingly, as the evidence available to us regarding fundraising revenue from this source was limited, our audit procedures with respect to cash donations had to be restricted to the amounts recorded in the financial records amounting to \$42,080.62. We therefore are unable to express an opinion whether cash donations for ANZGOG recorded are complete.

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the Financial Report* section of our report. We are independent of the registered entity in accordance with the auditor independence requirements of the *Australian Charities and Not-for-profits Commission Act 2012* (ACNC Act) and the ethical requirements of the Accounting Professional and Ethical Standards Board's *APES 110 Code of Ethics for Professional Accountants* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

#### Other information

Those charged with governance are responsible for the other information. The other information obtained at the date of this auditor's report is information included in the ANZGOG's annual report, but does not include the financial report and our auditor's report thereon.

BDO East Coast Partnership ABN 83 236 985 726 is a member of a national association of independent entities which are all members of BDO Australia Ltd ABN 77 050 110 275, an Australian company limited by guarantee. BDO East Coast Partnership and BDO Australia Ltd are members of BDO International Ltd, a UK company limited by guarantee, and form part of the international BDO network of independent member firms. Liability limited by a scheme approved under Professional Standards Legislation, other than for the acts or omissions of financial services licensees.



Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed on the other information obtained prior to the date of this auditor's report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

#### **Directors' Responsibility for the Financial Report**

The directors of the company are responsible for the preparation and fair presentation of the financial report in accordance with Australian Accounting Standards - Reduced Disclosure Requirements and the ACNC Act, and for such internal control as the directors determine is necessary to enable the preparation of the financial report that is free from material misstatement, whether due to fraud or error.

In preparing the financial report, directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the responsible entities either intends to liquidate the registered entity or to cease operations, or has no realistic alternative but to do so.

The directors are responsible for overseeing the company's financial reporting process.

#### **Auditor's responsibilities for the audit of the Financial Report**

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website (<http://www.auasb.gov.au/Home.aspx>) at:

[http://www.auasb.gov.au/auditors\\_responsibilities/ar4.pdf](http://www.auasb.gov.au/auditors_responsibilities/ar4.pdf)

This description forms part of our auditor's report.

#### **BDO East Coast Partnership**

A handwritten signature in black ink, appearing to read 'P. Cheeseman', is written over a faint, larger 'BDO' logo.

Paul Cheeseman  
Partner

Sydney, 27 September 2018

# Registration & Legislation

The Australian Business Number (ABN) is 69 138 649 028.

The Australian Company Number (ACN) is 138 649 028.

The Australian New Zealand Gynaecological Oncology Group is an Australian public company limited by guarantee trading under the name Australia New Zealand Gynaecological Oncology Group or ANZGOG.

ANZGOG is registered for charitable fundraising in all States and Territories of Australia:

- Western Australia – License No. 21334
- Queensland – Registration No. CH2213
- New South Wales – Charitable Fundraising No. CFN/21451
- South Australia – License No. CCP1765
- Tasmania – File No. F1A-331
- Australian Capital Territory – License No. 19000383
- Victoria – Registration No. 11419.13
- Northern Territory – Reference No. 2010-4117

ANZGOG is a Health Promotion Charity.

ANZGOG is endorsed as a deductible gift recipient under Section 30-15 of the Income Tax Assessment Act 1997.

ANZGOG operates under a comprehensive legislative environment, including the following state and federal laws:

## STATE

Annual Holidays Act 1944 (NSW)

Anti-discrimination Act 1977 (NSW)

Charitable Fundraising Act 1991 (NSW)

Charitable Trusts Act 1993 (NSW)

Crimes Act 1900 (NSW)

Fair Trading Act 1987 (NSW)

Health Records and Information Privacy Act 2002 (NSW)

Long Service Leave Act 1955 (NSW)

Public Holidays Act 2010 (NSW)

Work Health and Safety Act 2011 (NSW)

Workers Compensation Act 1987 (NSW)

Workplace Injury Management and Workers Compensation Act 1998 (NSW)

Workplace Surveillance Act 2005 (NSW)

## FEDERAL

A New Tax System (Goods and Services) Act 1999

Age Discrimination Act 2004

Australian Charities and Not-for-Profit Commission Act 2012

Charities Act 2013

Criminal Code Act 1995

Competition and Consumer Act 2010

Corporations Act 2001

Defamation Act 2005

Disability Discrimination Act 1992

Fair Work Act 2009

Fringe Benefits Tax Assessment Act 1986

Income Tax Assessment Act 1997

Privacy Act 1988

Racial Discrimination Act 1975

Sex Discrimination Act 1984

Workplace Gender Equality Act 2012

**ANZGOG's Head Office:**

Australia New Zealand Gynaecological Oncology Group  
Level 6, Chris O'Brien Lifehouse  
119-143 Missenden Road, CAMPERDOWN NSW 2050

**POSTAL:** Locked Bag M45, Missenden Road, NSW 2050

**Phone:** +61 2 8071 4880

**Fax:** + 61 2 8071 4888

**Email:** [admin@anzgog.org.au](mailto:admin@anzgog.org.au)

**ANZGOG's Melbourne Office:**

Women's Cancer Foundation  
Suite 122, Level 1,  
1 Queens Road, MELBOURNE VIC 3004

**Phone:** +61 3 9867 3515

**Email:** [contact@anzgog.org.au](mailto:contact@anzgog.org.au)



SaveTheBox  
GoForGynae  
[womenscancerfoundation.org](http://womenscancerfoundation.org)



@savetheboxnow



@anzgog



